Related Experiment Videos
Vincristine infusion with CHOP-CCNU in diffuse large-cell lymphoma
D V Jackson1, J B Craig, C L Spurr
1Piedmont Oncology Association and Cancer Center, Wake Forest University, Winston-Salem, North Carolina 27103.
Cancer Investigation
|January 1, 1990
Summary
Continuous infusion vincristine in a CHOP-CCNU regimen shows promise for advanced diffuse large-cell lymphoma. This approach offers rapid responses and durable complete remission with manageable toxicity in previously untreated patients.
Area of Science:
- Oncology
- Pharmacology
Background:
- Previous studies established the safety and efficacy of vincristine infusion for refractory non-Hodgkin's lymphoma.
- A need existed to evaluate this administration method in treatment-naive patients.
Purpose of the Study:
- To assess the efficacy and safety of continuous infusion vincristine within a CHOP-CCNU regimen for untreated advanced diffuse large-cell lymphoma.
Main Methods:
- Twenty-four patients with advanced diffuse large-cell lymphoma received repeated 5-day infusions of vincristine (0.25 mg/m2/day) as part of a CHOP-CCNU regimen.
- Toxicity, response rates, and long-term outcomes were monitored.
Main Results:
- Objective responses were observed in 75% of patients, with 54% achieving complete remission.
- Complete responses were durable, with 77% of responders remaining relapse-free.
- Nine patients (38%) remain alive with no evidence of disease 3.8 to 7.3 years post-treatment.
- Toxicity was generally mild to moderate, with neurotoxicity comparable to bolus vincristine.
Conclusions:
- Continuous infusion vincristine can be safely integrated into CHOP-type chemotherapy for non-Hodgkin's lymphoma.
- This method demonstrates potential for non-myelosuppressive, prolonged cell kill, suggesting its utility in future clinical trial designs for this malignancy.